Company: OSRH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001213900-25-109054
Chunk: 33

Company: OSR Holdings, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 exchange or other securities market on which the Common Stock is then being quoted or traded.

The conversion right on the above convertible bonds is classified as
other financial liabilities.

22

(17)Long-term debt

The Group has long-term debt agreements with individuals and
as of December 31, 2024, the total outstanding balance was $497,615 (4.6% interest rate at December 31, 2024), which matures in 2030.

(18)Post-employment benefits

The Group maintains a defined contribution
retirement benefit plan for its employees. The Group is obligated to pay fixed contributions to an independent fund, and the amount of
future retirement benefits to be paid to employees is determined by the contributions made to the fund, etc., and the investment income
generated from those contributions. Plan assets are managed independently from the Group's assets in a fund managed by a trustee.

Danatein’s pension plan has converted
from the DB type to the DC type at the end of March 31, 2017, and is obligated to pay severance payment as DB type which incurred before
the March 31, 2017.

Meanwhile, expenses recognized by the Group in relation to
the defined contribution retirement benefit plan for the nine months ended September 30, 2025 and 2024 are $401,449 and $93,458, respectively.

(19)Related party transactions

As of September 30, 2025, the Group's
related parties are as follows:

  Type           Related parties  Ultimate parent entity   Bellevue Capital Management LLC  Major shareholder of the Parent   BCM Europe AG  Subsidiaries   RMC, VAXIMM, Darnatein, OSR Holdings Co., Ltd.  Associates   Taction Co., Ltd.  Other related parties   Bellevue Global Life Sciences Investors LLC      Bellevue Global Life Sciences Acquisition Corp 

There are no sales and procurement transactions and treasury
transactions with related parties for the nine months ended September 30, 2025 and 2024.

Details of receivables and payables from related party transactions
as at September 30, 2025 and December 31, 2024 are as follows:

     September 30, 2025      Related parties   Short-term borrowings   BCM Europe AG  Major shareholder of the Parent  $860,000   Bellevue Global Life Sciences Acquisition Corp  Other related parties